Below are the most recent publications written about "Kidney Neoplasms" by people in Profiles.
-
Iskandar AS, Zarrabi KK, Tester WJ. Renal cell carcinoma: entering the age of biomarkers. Can J Urol. 2024 Aug; 31(4):11921-11930.
-
Antony MB, Kozel Z, Gopal N, Loebach L, Metwalli AR, Gurram S, Linehan WM, Ball MW. Cumulative Impact of Serial Partial Nephrectomy for the Treatment of Recurrent Renal Masses. J Urol. 2024 Sep; 212(3):431-440.
-
Wang T, Liu L, Rampisela D, Dong X, Keith KA, Benardete EA, Shan FY. A Cerebellar Tumor-to-Tumor Metastasis in a Patient With Von Hippel-Lindau Disease. Appl Immunohistochem Mol Morphol. 2024 May-Jun 01; 32(5):244-248.
-
Gomella PT, Solomon J, Ahdoot M, Gurram S, Lebastchi AH, Levy E, Krishnasamy V, Kassin MT, Chang R, Wood BJ, Linehan WM, Ball MW. Timing, incidence and management of delayed bleeding after partial nephrectomy in patients at risk for recurrent, bilateral, multifocal renal tumors. Urol Oncol. 2024 Jul; 42(7):222.e1-222.e7.
-
Jirka GW, Lefler DS, Russo J, Bashir B. Colon adenocarcinoma and Birt-Hogg-Dub? syndrome in a young patient: case report and exploration of pathologic implications. Cancer Biol Ther. 2023 Dec 31; 24(1):2184153.
-
Ganeshan D, Khatri G, Ali N, Avery R, Caserta MP, Chang SD, De Leon AD, Gupta RT, Lyshchik A, Michalski J, Nicola R, Pierorazio PM, Purysko AS, Smith AD, Taffel MT, Nikolaidis P. ACR Appropriateness Criteria? Staging of Renal Cell Carcinoma: 2022 Update. J Am Coll Radiol. 2023 05; 20(5S):S246-S264.
-
Demidova EV, Serebriiskii IG, Vlasenkova R, Kelow S, Andrake MD, Hartman TR, Kent T, Virtucio J, Rosen GL, Pomerantz RT, Dunbrack RL, Golemis EA, Hall MJ, Chen DYT, Daly MB, Arora S. Candidate variants in DNA replication and repair genes in early-onset renal cell carcinoma patients referred for germline testing. BMC Genomics. 2023 Apr 24; 24(1):212.
-
Foss HE, Krewson BD, Simhal RK, Wang KR, Shah MS. Squamous cell carcinoma of the renal pelvis masquerading as xanthogranulomatous pyelonephritis. Can J Urol. 2023 04; 30(2):11502-11504.
-
Ligon JA, Sundby RT, Wedekind MF, Arnaldez FI, Del Rivero J, Wiener L, Srinivasan R, Spencer M, Carbonell A, Lei H, Shern J, Steinberg SM, Figg WD, Peer CJ, Zimmerman S, Moraly J, Xu X, Fox S, Chan K, Barbato MI, Andresson T, Taylor N, Pacak K, Killian JK, Dombi E, Linehan WM, Miettinen M, Piekarz R, Helman LJ, Meltzer P, Widemann B, Glod J. A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma. Clin Cancer Res. 2023 01 17; 29(2):341-348.
-
Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy. J Immunother Cancer. 2022 11; 10(11).